Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00559585
Registration number
NCT00559585
Ethics application status
Date submitted
15/11/2007
Date registered
16/11/2007
Date last updated
9/11/2015
Titles & IDs
Public title
Methotrexate-Inadequate Response Study
Query!
Scientific title
A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate
Query!
Secondary ID [1]
0
0
EUDRACT # 2007-005434-37
Query!
Secondary ID [2]
0
0
IM101-174
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis (RA)
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Subcutaneous (SC) Abatacept
Treatment: Drugs - Intravenous (IV) Abatacept
Active Comparator: Subcutaneous (SC) Abatacept - Participants received 125 mg weekly SC abatacept injections (with an intravenous [IV] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
Active Comparator: Intravenous (IV) Abatacept - Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).
Treatment: Drugs: Subcutaneous (SC) Abatacept
Participants received 125 mg weekly SC abatacept injections (with an intravenous [IV] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
Treatment: Drugs: Intravenous (IV) Abatacept
Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).
500mg (for body weight up to 60 kg)
750 mg (body weight between 61 and 100 kg)
1g (body weight above 100 kg)infusions
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Double-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169
Query!
Assessment method [1]
0
0
The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joints, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).
Query!
Timepoint [1]
0
0
Day 169
Query!
Primary outcome [2]
0
0
Anti-TNF Failure Sub-Study Double Blind Period : Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Response in Anti-TNF Failure Population
Query!
Assessment method [2]
0
0
Serum samples from all treated adult participants with active rheumatoid arthritis who were from the Anti-TNF failure population were screened for the presence of drug-specific antibodies using Enzyme Linked Immunoabsorbant Assay (ELISA). The number of participants who had the presence of anti-abatacept antibodies or anti-CTLA-4 antibodies present in their serum are summarized.
Query!
Timepoint [2]
0
0
Days 85, and 169 and postvisits on Days 28, 56, and 85
Query!
Secondary outcome [1]
0
0
Double-blind Period: Number of Participants Achieving ACR 50 and ACR 70 Responses at Day 169
Query!
Assessment method [1]
0
0
The ACR 50 definition of improvement is a 50% improvement from baseline in the number of tender and swollen joint counts, and a 50% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein). ACR 70 is defined similarly with 70% improvements from baseline for tender and swollen joint counts and 3 out of 5 core measures.
Query!
Timepoint [1]
0
0
Day 169
Query!
Secondary outcome [2]
0
0
Double-blind Period: Mean Baseline Health Assessment Questionnaire Disability Index (HAQ-DI) for Participants With Assessments at Day 169
Query!
Assessment method [2]
0
0
The disability section of the full HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. Higher scores=greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered.
Query!
Timepoint [2]
0
0
Day 169
Query!
Secondary outcome [3]
0
0
Double-blind Period: Adjusted Mean Change From Baseline to Day 169 in HAQ-DI
Query!
Assessment method [3]
0
0
The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0.
Query!
Timepoint [3]
0
0
Baseline to Day 169
Query!
Secondary outcome [4]
0
0
Double-blind Period: Number of Participants Achieving Clinically Meaningful HAQ-DI Response at Day 169
Query!
Assessment method [4]
0
0
The disability section of the full HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3=unable to do. Higher scores=greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ-DI response=an improvement of at least 0.3 units from baseline in HAQ-DI.
Query!
Timepoint [4]
0
0
Day 169
Query!
Secondary outcome [5]
0
0
Double-blind Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, or AEs Leading to Discontinuation
Query!
Assessment method [5]
0
0
AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related SAE=possibly, probably, or certainly related to study drug
Query!
Timepoint [5]
0
0
Day 1 to 56 days after last dose in short-term or first dose in the long-term, whichever occurs first.
Query!
Secondary outcome [6]
0
0
Anti-TNF Failure Sub-study Double-blind Period: Number of Participants With SAEs, AEs Leading to Discontinuation or Who Died
Query!
Assessment method [6]
0
0
AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
Query!
Timepoint [6]
0
0
Day 1 to 56 days after last dose in short-term or first dose in the long-term, whichever occurs first.
Query!
Secondary outcome [7]
0
0
Double-blind Period: Number of Participants With AEs of Special Interest
Query!
Assessment method [7]
0
0
AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs: all infections,serious infections,and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (prespecified AEs occurring within 1 hr of start of infusion), peri-infusional AEs (prespecified AEs occurring within 24 hrs of the start of infusion), system injection reactions, and local injection site reactions
Query!
Timepoint [7]
0
0
Day 1 up to 56 days post last dose in short- term period or first dose in the long -term period, whichever occurs first.
Query!
Secondary outcome [8]
0
0
Double-blind Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements
Query!
Assessment method [8]
0
0
Vital sign measurements were performed for participants before and after infusion/subcutaneous injection of study medication at each visit and included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.
Query!
Timepoint [8]
0
0
Day 1 through end of short-term period (Day 169)
Query!
Secondary outcome [9]
0
0
Double-blind Period: Number of Participants With Hematology Laboratory Test Results Meeting the Criteria for Marked Abnormality
Query!
Assessment method [9]
0
0
ULN=upper limit of normal; LLN=lower limit of normal; BL= baseline. Marked abnormality criteria: Hemoglobin: >3 g/dL decrease from BL; hematocrit: <0.75*BL; erythrocytes: <0.75*BL; platelets: <0.67*LLN/>1.5*ULN, or if BL<LLN, use <0.5*BL and <100,000 mm^3; leukocytes: <0.75*LLN/>1.25*ULN, or if BL<LLN use <0.8*BL or >ULN, or if BL>ULN, use >1.2*BL or <LLN; neutrophils+bands: <1.0*10^3 c/uL; eosinophils: >0.750*10^3 c/uL; basophils: >400 mm^3; monocytes: >2000 mm^3; lymphocytes: <0.750*10^3 c/uL/>7.50*10^3 c/uL.
Query!
Timepoint [9]
0
0
Day 1 through end of short-term period (Day 169)
Query!
Secondary outcome [10]
0
0
Double-blind Period: Number of Participants With Liver Function Laboratory Test Results Meeting the Criteria for Marked Abnormality
Query!
Assessment method [10]
0
0
Marked abnormality criteria: Alkaline phosphatase (ALP): >2*ULN, or if BL>ULN, use >3*BL; aspartate aminotransferase (AST): >3*ULN, or if BL>ULN, use >4*BL; alanine aminotransferase (ALT): >3*ULN, or if BL>ULN, use >4*BL; G-glutamyl transferase (GGT): >2* ULN, or if BL>ULN, use >3*BL; bilirubin: >2* ULN, or if BL>ULN, use >4*BL; blood urea nitrogen: >2* BL; creatinine: >1.5*BL
Query!
Timepoint [10]
0
0
Day 1 through end of short-term period (Day 169)
Query!
Secondary outcome [11]
0
0
Double-blind Period: Number of Participants With Electrolyte Laboratory Test Results Meeting the Criteria for Marked Abnormality
Query!
Assessment method [11]
0
0
Marked abnormality criteria: Sodium: <0.95*LLN/>1.05*ULN, or if BL<LLN, use <0.95* BL or >ULN, or if BL>ULN, use>1.05* BL or <LLN; potassium: <0.9* LLN/>1.1*ULN, or if BL<LLN then use <0.9* BL or >ULN, or if BL>ULN, use>1.1* BL or <LLN; chlorine: <0.9*LLN/>1.1* ULN, or if BL<LLN, use <0.9*BL or >ULN, or if BL>ULN, use>1.1*BL or <LLN; calcium: <0.8* LLN/>1.2* ULN, or if BL<LLN, use <0.75*BL or >ULN, or if BL>ULN, use>1.25* BL or <LLN; phosphorous: <0.75* LLN/>1.25*ULN, or if BL<LLN, use 0.67*BL or >ULN, or if BL>ULN, use>1.33* BL or <LLN
Query!
Timepoint [11]
0
0
Day 1 through end of short-term period (Day 169)
Query!
Secondary outcome [12]
0
0
Double-blind Period: Minimum Observed Serum Concentration of Abatacept
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Days 57, 85, 113, 120, 127, 134, 141, and 169
Query!
Secondary outcome [13]
0
0
Anti-TNF Failure Sub-study Double-blind Period: Minimum Observed Serum Concentration (Cmin) of Abatacept
Query!
Assessment method [13]
0
0
Serum concentrations of abatacept were analyzed using a validated ELISA. Steady-state trough observed concentration in serum (Cminss) was measured in µg/mL. Samples were obtained on Days 57, 85, 113, 120, 127, 134, 141, and 169.
Query!
Timepoint [13]
0
0
Days 57, 85, 113, 120, 127, 134, 141, and 169 (ST Period)
Query!
Secondary outcome [14]
0
0
Double-blind Period: Maximum Observed Serum Concentration of Abatacept
Query!
Assessment method [14]
0
0
Query!
Timepoint [14]
0
0
End of infusion on Days 1 and 113 for IV infusion and in the dosing interval of Days 113 to 120 for subcutaneous
Query!
Secondary outcome [15]
0
0
Anti-TNF Failure Substudy Double Blind Period: Geometric Mean Maximum Observed Serum Concentration of Abatacept
Query!
Assessment method [15]
0
0
Serum concentrations of abatacept were analyzed using a validated enzyme-linked immunosorbent assay (ELISA). Samples were obtained on Days 57, 85, 113, 120, 127, 134, 141, and 169. Cmax was measured in micrograms per milliliter (µg/mL).
Query!
Timepoint [15]
0
0
End of infusion on Days 1 and 113 for IV infusion and in the dosing interval of Days 113 to 120 for subcutaneous
Query!
Secondary outcome [16]
0
0
Double-blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept
Query!
Assessment method [16]
0
0
Query!
Timepoint [16]
0
0
Dosing interval between Days 113 and 141 (TAU=28 days)
Query!
Secondary outcome [17]
0
0
Anti-TNF Failure Sub-study Double Blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept
Query!
Assessment method [17]
0
0
Serum concentrations of abatacept were analyzed using a validated ELISA. AUC(TAU) was measured as µg*h/mL. Samples for AUC (TAU) were obtained on Days 113, 120, 127, 134, and 141.
Query!
Timepoint [17]
0
0
Dosing Interval between Days 113 and 141 (TAU=28 days)
Query!
Secondary outcome [18]
0
0
Double-blind Period: Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Responses Over Time by Enzyme Linked Immunoabsorbant Assay (ELISA)
Query!
Assessment method [18]
0
0
Serum samples from all treated adult participants with active rheumatoid arthritis were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept (anti-ABA) or anti-CTLA4 antibody (anti-CTLA4).
Query!
Timepoint [18]
0
0
Days 85, and 169 and postvisits on Days 28, 56, and 85
Query!
Secondary outcome [19]
0
0
Double-blind Period: Time-matched Median Percent Change From Baseline in Levels of Serum C-reactive Protein Over the Short-term Period
Query!
Assessment method [19]
0
0
C-reactive protein is an acute phase reactant protein that is a clinical marker for rheumatoid arthritis. Time-matched median percent change from baseline= (time-matched baseline value - Post-baseline value)/time-matched baseline value*100, where the time-matched baseline value represents the median baseline value for only that cohort of participants with measurements available at that visit.
Query!
Timepoint [19]
0
0
Baseline to Days 15, 29, 57, 85, 113, 141, and 169
Query!
Secondary outcome [20]
0
0
Double-blind Period: Number of Participants With Positive Anti-abatacept Responses Over Time by Electrochemiluminescence Immunoassay Among the First 10% of Participants Randomized
Query!
Assessment method [20]
0
0
An electrochemiluminescence immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; abatacept molecule). Ig and/or Junction (JNCT) category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a postbaseline titer higher than Baseline, or any postbaseline positivity if Baseline value was missing. Trt=treatment.
Query!
Timepoint [20]
0
0
Days 85, and 169 and postvisits on Days 28, 56, and 85
Query!
Secondary outcome [21]
0
0
Double-blind Period: Number of Participants Seroconverting by Day 169 According to Status (Negative or Positive) at Baseline
Query!
Assessment method [21]
0
0
Rheumatoid factor (RF) is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process.
Query!
Timepoint [21]
0
0
Baseline to Day 169
Query!
Secondary outcome [22]
0
0
Open-Label LT Period: Number of Participants Achieving ACR 20 Response at Days 169, 729, 1261, and 1821
Query!
Assessment method [22]
0
0
The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joints, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).
Query!
Timepoint [22]
0
0
Days 169, 729, 1261, 1821
Query!
Secondary outcome [23]
0
0
Open-Label LT Period: Number of Participants Achieving ACR 50 and ACR 70 Responses at Days 169, 729, 1261, 1821
Query!
Assessment method [23]
0
0
The ACR 50 definition of improvement is a 50% improvement from baseline in the number of tender and swollen joint counts, and a 50% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein). ACR 70 is defined similarly with 70% improvements from baseline for tender and swollen joint counts and 3 out of 5 core measures.
Query!
Timepoint [23]
0
0
Days 169, 729, 1261, 1821
Query!
Secondary outcome [24]
0
0
Open-Label LT Period: Mean Change From Baseline in Disease Activity Score in 28 Joints (DAS28) Using C-reactive Protein (CRP) at Days 169, 729, 1261, 1821
Query!
Assessment method [24]
0
0
The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is > 5.1, low disease activity is < 3.2 and remission is < 2.6. A clinically significant response= decrease in DAS28 score of >1.2 from baseline.
Query!
Timepoint [24]
0
0
Days 169, 729, 1261, 1821
Query!
Secondary outcome [25]
0
0
Open-Label LT Period: Number of Participants Achieving DAS 28 Remission at Days 169, 729, 1261, 1821
Query!
Assessment method [25]
0
0
The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is > 5.1, low disease activity is < 3.2 and remission is < 2.6.
Query!
Timepoint [25]
0
0
Days 169, 729, 1261, 1821
Query!
Secondary outcome [26]
0
0
Open-Label LT Period: Number of Participants Achieving DAS 28 Low Disease Activity (LDA) at Days 169, 729, 1261, 1821
Query!
Assessment method [26]
0
0
The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is > 5.1, low disease activity is < 3.2 and remission is < 2.6.
Query!
Timepoint [26]
0
0
Days 169, 729, 1261, 1821
Query!
Secondary outcome [27]
0
0
Open-Label LT Period: Number of Participants With HAQ-DI Response at Days 169, 729, 1261, 1821
Query!
Assessment method [27]
0
0
The disability section of the full HAQ includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. HAQ-DI overall score ranges from a minimum of 0 to a maximum of 3.0. HAQ response was defined as an improvement (reduction) from baseline (Day 1) of at least 0.3 units in the HAQ score.
Query!
Timepoint [27]
0
0
Days 169, 729, 1261, 1821
Query!
Secondary outcome [28]
0
0
Open-Label LT Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, or AEs Leading to Discontinuation
Query!
Assessment method [28]
0
0
AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related SAE=possibly, probably, or certainly related to study drug
Query!
Timepoint [28]
0
0
End of ST Period (Day 169) to last dose plus 85 days, up to 5 years (September 2014)
Query!
Secondary outcome [29]
0
0
Open-Label LT Period: Number of Participants With AEs of Special Interest
Query!
Assessment method [29]
0
0
AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs: all infections, serious infections, and opportunistic infections; autoimmune disorders; malignancies; system injection reactions, and local injection site reactions.
Query!
Timepoint [29]
0
0
End of ST Period (Day 169) to last dose plus 85 days, up to 5 years (September 2014)
Query!
Secondary outcome [30]
0
0
Open-Label LT Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements
Query!
Assessment method [30]
0
0
Vital sign assessments were performed in the LT period at 12-week intervals and at a yearly visit (at 16-week intervals) and, for participants who withdrew from the study prematurely, 7 days after the last dose of SC abatacept. Vital signs included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.
Query!
Timepoint [30]
0
0
End of ST Period (Day 169) to last dose plus 7 days, up to 5 years (September 2014)
Query!
Secondary outcome [31]
0
0
Open-Label LT Period: Number of Participants With Clinically Significant Laboratory Abnormalities
Query!
Assessment method [31]
0
0
Laboratory assessments were performed in the LT period at 12-week intervals and at a yearly visit and, for participants who withdrew from the study prematurely, 7 days after the last dose of SC abatacept. Abnormalities were determined to be clinically significant by the investigator.
Query!
Timepoint [31]
0
0
End of ST Period (Day 169) to last dose plus 7 days, up to 5 years (September 2014)
Query!
Eligibility
Key inclusion criteria
For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com
- Subjects who are considered methotrexate inadequate responders
- 10 or more swollen joints (66 joint count) and 12 or more tender joints (68 joint
count)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Subjects who failed one or multiple anti-tumor necrosis factor (TNF) therapies
- Subjects who meet diagnostic criteria for any other rheumatic disease (e.g., lupus
erythematous)
- Subjects with active vasculitis of a major organ system (except for subcutaneous
rheumatoid nodules)
- Subjects with severe chronic or recurrent bacterial infections
- Subjects who have received treatment with rituximab
An Anti-TNF Failure Sub-study was initiated (recruited separately from Main study) using
the same treatment as the Main study in order to assess the immunogenicity and safety in
the Anti-TNF Failure population. The Sub-study terminated due to low recruitment and
participants were permitted to roll into the LT Open Label Period.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/09/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
2492
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Local Institution - St Leonards
Query!
Recruitment hospital [2]
0
0
Local Institution - Cairns
Query!
Recruitment hospital [3]
0
0
Local Institution - Maroochydore
Query!
Recruitment hospital [4]
0
0
Local Institution - Woodville
Query!
Recruitment hospital [5]
0
0
Local Institution - Heidelberg
Query!
Recruitment hospital [6]
0
0
Local Institution - Shenton Park
Query!
Recruitment postcode(s) [1]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [2]
0
0
QLD 4870 - Cairns
Query!
Recruitment postcode(s) [3]
0
0
4558 - Maroochydore
Query!
Recruitment postcode(s) [4]
0
0
5011 - Woodville
Query!
Recruitment postcode(s) [5]
0
0
3081 - Heidelberg
Query!
Recruitment postcode(s) [6]
0
0
6008 - Shenton Park
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Idaho
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Illinois
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maryland
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Massachusetts
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Michigan
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Mississippi
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Missouri
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Nebraska
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Jersey
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New Mexico
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New York
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
North Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Ohio
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Oklahoma
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Oregon
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Pennsylvania
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Rhode Island
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
South Carolina
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Tennessee
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Texas
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Virginia
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Washington
Query!
Country [31]
0
0
Argentina
Query!
State/province [31]
0
0
Buenos Aires
Query!
Country [32]
0
0
Argentina
Query!
State/province [32]
0
0
Santa Fe
Query!
Country [33]
0
0
Argentina
Query!
State/province [33]
0
0
Cordoba
Query!
Country [34]
0
0
Argentina
Query!
State/province [34]
0
0
Tucuman
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Bruxelles
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Hasselt
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Leuven
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Wilrijk
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Yvoir
Query!
Country [40]
0
0
Brazil
Query!
State/province [40]
0
0
Goias
Query!
Country [41]
0
0
Brazil
Query!
State/province [41]
0
0
Minas Gerais
Query!
Country [42]
0
0
Brazil
Query!
State/province [42]
0
0
Parana
Query!
Country [43]
0
0
Brazil
Query!
State/province [43]
0
0
Pernambuco
Query!
Country [44]
0
0
Brazil
Query!
State/province [44]
0
0
Rio Grande Do Sul
Query!
Country [45]
0
0
Brazil
Query!
State/province [45]
0
0
Sao Paulo
Query!
Country [46]
0
0
Brazil
Query!
State/province [46]
0
0
Rio De Janeiro
Query!
Country [47]
0
0
Canada
Query!
State/province [47]
0
0
Manitoba
Query!
Country [48]
0
0
Canada
Query!
State/province [48]
0
0
Newfoundland and Labrador
Query!
Country [49]
0
0
Canada
Query!
State/province [49]
0
0
Ontario
Query!
Country [50]
0
0
Canada
Query!
State/province [50]
0
0
Quebec
Query!
Country [51]
0
0
Canada
Query!
State/province [51]
0
0
Saskatchewan
Query!
Country [52]
0
0
Chile
Query!
State/province [52]
0
0
Metropolitana
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Bordeaux Cedex
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Brest Cedex
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Chambray Les Tours
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Le Mans
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Lille Cedex
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Marseille
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Nice Cedex 3
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Paris Cedex 13
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Paris Cedex 14
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Poitiers
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Strasbourg Cedex
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Berlin
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Leipzig
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Muenchen
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Munchen
Query!
Country [68]
0
0
Greece
Query!
State/province [68]
0
0
Heraklion Crete
Query!
Country [69]
0
0
Hungary
Query!
State/province [69]
0
0
Budapest
Query!
Country [70]
0
0
Hungary
Query!
State/province [70]
0
0
Debrecen
Query!
Country [71]
0
0
India
Query!
State/province [71]
0
0
Andhra Pradesh
Query!
Country [72]
0
0
India
Query!
State/province [72]
0
0
Gujarat
Query!
Country [73]
0
0
India
Query!
State/province [73]
0
0
Karnataka
Query!
Country [74]
0
0
India
Query!
State/province [74]
0
0
Bangalore
Query!
Country [75]
0
0
India
Query!
State/province [75]
0
0
Hyderabad
Query!
Country [76]
0
0
India
Query!
State/province [76]
0
0
Lucknow
Query!
Country [77]
0
0
India
Query!
State/province [77]
0
0
New Delhi
Query!
Country [78]
0
0
Ireland
Query!
State/province [78]
0
0
Dublin
Query!
Country [79]
0
0
Italy
Query!
State/province [79]
0
0
Napoli
Query!
Country [80]
0
0
Italy
Query!
State/province [80]
0
0
Padova
Query!
Country [81]
0
0
Italy
Query!
State/province [81]
0
0
Pavia
Query!
Country [82]
0
0
Italy
Query!
State/province [82]
0
0
Roma
Query!
Country [83]
0
0
Italy
Query!
State/province [83]
0
0
Siena
Query!
Country [84]
0
0
Korea, Republic of
Query!
State/province [84]
0
0
Sungdong-Gu
Query!
Country [85]
0
0
Korea, Republic of
Query!
State/province [85]
0
0
Daegu
Query!
Country [86]
0
0
Korea, Republic of
Query!
State/province [86]
0
0
Daejeon
Query!
Country [87]
0
0
Korea, Republic of
Query!
State/province [87]
0
0
Seoul
Query!
Country [88]
0
0
Mexico
Query!
State/province [88]
0
0
Baja California
Query!
Country [89]
0
0
Mexico
Query!
State/province [89]
0
0
Distrito Federal
Query!
Country [90]
0
0
Mexico
Query!
State/province [90]
0
0
Jalisco
Query!
Country [91]
0
0
Mexico
Query!
State/province [91]
0
0
Michioacan
Query!
Country [92]
0
0
Mexico
Query!
State/province [92]
0
0
Yucatan
Query!
Country [93]
0
0
Mexico
Query!
State/province [93]
0
0
Aguascalientes
Query!
Country [94]
0
0
Mexico
Query!
State/province [94]
0
0
Chihuahua
Query!
Country [95]
0
0
Mexico
Query!
State/province [95]
0
0
Nuevo Leon
Query!
Country [96]
0
0
Mexico
Query!
State/province [96]
0
0
Queretaro
Query!
Country [97]
0
0
Mexico
Query!
State/province [97]
0
0
San Luis Potosi
Query!
Country [98]
0
0
Netherlands
Query!
State/province [98]
0
0
Leeuwarden
Query!
Country [99]
0
0
Peru
Query!
State/province [99]
0
0
Callao
Query!
Country [100]
0
0
Peru
Query!
State/province [100]
0
0
Lima
Query!
Country [101]
0
0
Poland
Query!
State/province [101]
0
0
Bialystok
Query!
Country [102]
0
0
Poland
Query!
State/province [102]
0
0
Bydgoszcz
Query!
Country [103]
0
0
Poland
Query!
State/province [103]
0
0
Konskie
Query!
Country [104]
0
0
Poland
Query!
State/province [104]
0
0
Krakow
Query!
Country [105]
0
0
Poland
Query!
State/province [105]
0
0
Poznan
Query!
Country [106]
0
0
Poland
Query!
State/province [106]
0
0
Torun
Query!
Country [107]
0
0
Poland
Query!
State/province [107]
0
0
Warszawa
Query!
Country [108]
0
0
Russian Federation
Query!
State/province [108]
0
0
Ekaterinburg
Query!
Country [109]
0
0
Russian Federation
Query!
State/province [109]
0
0
Moscow
Query!
Country [110]
0
0
Russian Federation
Query!
State/province [110]
0
0
Yaroslavl
Query!
Country [111]
0
0
South Africa
Query!
State/province [111]
0
0
Gauteng
Query!
Country [112]
0
0
South Africa
Query!
State/province [112]
0
0
Kwa Zulu Natal
Query!
Country [113]
0
0
South Africa
Query!
State/province [113]
0
0
Western Cape
Query!
Country [114]
0
0
Taiwan
Query!
State/province [114]
0
0
Kaohsiung
Query!
Country [115]
0
0
Taiwan
Query!
State/province [115]
0
0
Taichung
Query!
Country [116]
0
0
Turkey
Query!
State/province [116]
0
0
Denizli
Query!
Country [117]
0
0
Turkey
Query!
State/province [117]
0
0
Edirne
Query!
Country [118]
0
0
Turkey
Query!
State/province [118]
0
0
Gaziantep
Query!
Country [119]
0
0
United Kingdom
Query!
State/province [119]
0
0
Cambridgeshire
Query!
Country [120]
0
0
United Kingdom
Query!
State/province [120]
0
0
Glamorgan
Query!
Country [121]
0
0
United Kingdom
Query!
State/province [121]
0
0
Greater London
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
Hampshire
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
Tyne And Wear
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept
yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in
participants with rheumatoid arthritis and an inadequate response to current methotrexate
therapy.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00559585
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00559585
Download to PDF